Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of ...

Choosing a random dividend stock out of a hat won't do, though. Some are much more attractive than others. Which ones should ...

Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Amgen is a significant win for IPG Mediabrands after Amazon moved its massive media business from Initiative to WPP and ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...